ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0881

Circulating Monocytes with High Interferon Signature as Precursors to Osteopontin Expressing Lung Macrophages in Patients with Systemic Sclerosis and Progressive Interstitial Lung Disease

Shu-Ju Lin1, Kimberly Taylor2, Shen Yang3, Qinwei Chen4, Shehani Alexander1, Ye Cao5, Takanori Sasaki5, Deepak Rao5, Nunzio Bottini6, Francesco Boin3 and Richard Ainsworth4, 1Cedars-Sinai Medical Center, Los Angeles, CA, 2UC San Francisco, San Francisco, CA, 3Cedars-Sinai Medical Center, Beverly Hills, CA, 4Cedars Sinai Medical Center, Los Angeles, CA, 5Brigham and Women's Hospital, Boston, MA, 6Cedars Sinai Medical Center, Beverly Hills, CA

Meeting: ACR Convergence 2025

Keywords: interferon, interstitial lung disease, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: Abstracts: Systemic Sclerosis & Related Disorders – Clinical II (0879–0884)

Session Type: Abstract Session

Session Time: 10:30AM-10:45AM

Background/Purpose: Circulating monocytes with pro-inflammatory and pro-fibrotic phenotype have been implicated in SSc-ILD pathogenesis, but their potential trajectory to mature cell lineage macrophages driving organ-specific damage is not well defined.Evidence suggests that osteopontin expressing macrophages likely contribute to fibrotic mechanisms in SSc-ILD. We sought to characterize specific myeloid subpopulations associated with SSc-ILD progression and establish potential precursor relationships with lung macrophages.

Methods: Single-cell RNA-seq (scRNA-seq) was performed on peripheral blood obtained from 60 SSc patients meeting 2013 ACR/EULAR criteria. Unsupervised clustering identified two subpopulations of monocytes with type I interferon signatures. Differential expression and subtype correlation analyses against %change in forced vital capacity (FVC, liter) per year from baseline were conducted in subjects with SSc-ILD (n=40). Transcription factor (TF) analysis was conducted for progressive ( >10% decrease in FVC) and non-progressive SSc-ILD patients. Reprocessed publicly available scRNA-seq data from SSc-ILD lungs were used to perform trajectory analysis.

Results: Clustering and annotation of myeloid cells identified 11 myeloid cell types and two subclusters (CD74+ and CD74-) of an “ISG15-hi” monocyte population expressing high levels of interferon (IFN)-inducible markers (Fig.1A). The CD74+ subpopulation showed further enrichment for genes involved in “Response to type I IFN signaling” (FDR = 6.82 x 10-4) whilst the CD74- subpopulation upregulated genes involved in “Leukocyte cell-to-cell adhesion” (FDR = 3.61 x 10-3) (Fig.1B,D). Correlation analysis of cell type proportions against FVC %-change for SSc-ILD patients (Fig.1C) revealed a Pearson correlation of 0.60 (p=1.9×10-4) in the CD74+ “ISG15-hi” monocyte population. In the CD74+ subpopulation, progressive SSc-ILD patients upregulated genes involved in “Myeloid differentiation” (FDR = 2.90 x 10-2) (Fig.2A) and further showed increased activity for TFs previously reported as specific regulators in osteopontin expressing lung macrophages (Mac-SPP1-lung) from SSc-ILD patients including ATF5 and MAFF (Fig.2B). A reanalysis of SSc-ILD lung scRNA-seq data identified a population of “ISG15-hi” classical monocytes CMos-ISG15-lung and the previously reported Mac-SPP1-lung (Fig.3A). Trajectory analysis predicted a differentiation trajectory from CMos-ISG15-lung to Mac-SPP1-lung (Fig. 3B).

Conclusion: We identified a novel CD74⁺ subcluster within ISG15-high circulating monocytes, marked by strong type I IFN-inducible gene expression and significantly negatively associated with progressive SSc-ILD. This population may serve as a precursor to pro-fibrotic, osteopontin-expressing lung macrophages, suggesting a pathogenic role in SSc-ILD.

Supporting image 1Fig. 1. A. UMAP of myeloid cells showing subclustering of monocyte cluster with type I IFN signature. B. Volcano plot of subcluster markers. C. Correlation of cluster frequencies with change in %fvc from baseline for SSc-ILD patients. D. Pathways for classical monocyte ISG15 subclusters.

Supporting image 2Fig. 2. A. Volcano plot for differential expression of progressive vs non-progressive SSc-ILD in CD74+ subpopulation. B. SCENIC TF analysis of subclusters split by disease progression.

Supporting image 3Fig. 3. A. DotPlot for markers of lung monocytes and osteopontin expressing macrophages. B. UMAP of clusters and trajectory analysis. Ref 1: Ann Rheum Dis. 2019 Aug 12;78(10):1379_1387


Disclosures: S. Lin: None; K. Taylor: None; S. Yang: None; Q. Chen: None; S. Alexander: None; Y. Cao: None; T. Sasaki: None; D. Rao: Abbvie, 6, Aditum, 2, AnaptysBio, 2, AstraZeneca, 2, Biogen, 2, Dragonfly, 2, Epana, 1, HiFiBio Therapeutics, 2, Janssen, 5, Merck/MSD, 2, 5, Site Tx, 2; N. Bottini: Merck/MSD, 2; F. Boin: Adicet Bio, 2, Boehringer Ingelheim, 1, Janssen Pharmaceuticals, 6; R. Ainsworth: None.

To cite this abstract in AMA style:

Lin S, Taylor K, Yang S, Chen Q, Alexander S, Cao Y, Sasaki T, Rao D, Bottini N, Boin F, Ainsworth R. Circulating Monocytes with High Interferon Signature as Precursors to Osteopontin Expressing Lung Macrophages in Patients with Systemic Sclerosis and Progressive Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/circulating-monocytes-with-high-interferon-signature-as-precursors-to-osteopontin-expressing-lung-macrophages-in-patients-with-systemic-sclerosis-and-progressive-interstitial-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/circulating-monocytes-with-high-interferon-signature-as-precursors-to-osteopontin-expressing-lung-macrophages-in-patients-with-systemic-sclerosis-and-progressive-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology